Loading...

Gopalan Sethuraman

Title(s)Associate Professor of Research Neurology
Phone+1 858 964 0794
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Wang G, Berry S, Xiong C, Hassenstab J, Quintana M, McDade EM, Delmar P, Vestrucci M, Sethuraman G, Bateman RJ. A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease. Stat Med. 2018 09 20; 37(21):3047-3055. PMID: 29761523.
      View in: PubMed
    2. Reed C, Belger M, Dell'Agnello G, Kahle-Wrobleski K, Sethuraman G, Hake A, Raskin J, Henley D. Representativeness of European clinical trial populations in mild Alzheimer's disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study. Alzheimers Res Ther. 2018 04 03; 10(1):36. PMID: 29615123.
      View in: PubMed
    3. Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H, Dowsett SA, Pontecorvo MJ, Dean RA, Demattos R. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement. 2016 Feb; 12(2):110-120. PMID: 26238576.
      View in: PubMed
    4. Liu-Seifert H, Siemers E, Holdridge KC, Andersen SW, Lipkovich I, Carlson C, Sethuraman G, Hoog S, Hayduk R, Doody R, Aisen P. Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years. Alzheimers Dement (N Y). 2015 Sep; 1(2):111-121. PMID: 29854931.
      View in: PubMed
    5. Doody RS, Raman R, Sperling RA, Seimers E, Sethuraman G, Mohs R, Farlow M, Iwatsubo T, Vellas B, Sun X, Ernstrom K, Thomas RG, Aisen PS. Peripheral and central effects of ?-secretase inhibition by semagacestat in Alzheimer's disease. Alzheimers Res Ther. 2015; 7(1):36. PMID: 26064192.
      View in: PubMed
    6. Henley DB, Sundell KL, Sethuraman G, Dowsett SA, May PC. Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings. Curr Med Res Opin. 2014 Oct; 30(10):2021-32. PMID: 24983746.
      View in: PubMed
    7. Henley DB, Sundell KL, Sethuraman G, Schneider LS. Adverse events and dropouts in Alzheimer's disease studies: what can we learn? Alzheimers Dement. 2015 Jan; 11(1):24-31. PMID: 24613705.
      View in: PubMed
    8. Habteab Ghebretinsae A, Molenberghs G, Dmitrienko A, Offen W, Sethuraman G. Assessment of type I error rate associated with dose-group switching in a longitudinal Alzheimer trial. J Biopharm Stat. 2014; 24(3):660-84. PMID: 24697817.
      View in: PubMed
    9. Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS, Siemers E, Sethuraman G, Mohs R. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25; 369(4):341-50. PMID: 23883379.
      View in: PubMed
    10. Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012 Jul; 8(4):261-71. PMID: 22672770.
      View in: PubMed
    11. Yu P, Dean RA, Hall SD, Qi Y, Sethuraman G, Willis BA, Siemers ER, Martenyi F, Tauscher JT, Schwarz AJ. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia. J Alzheimers Dis. 2012; 32(2):373-85. PMID: 22796873.
      View in: PubMed
    12. Henley DB, Sundell KL, Sethuraman G, Siemers ER. Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies. Alzheimers Dement. 2012 Sep; 8(5):407-16. PMID: 22138370.
      View in: PubMed
    13. Lachno DR, Romeo MJ, Siemers ER, Vanderstichele H, Coart E, Konrad RJ, Zajac JJ, Talbot JA, Jensen HF, Sethuraman G, Demattos RB, May PC, Dean RA. Validation of ELISA methods for quantification of total tau and phosporylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies. J Alzheimers Dis. 2011; 26(3):531-41. PMID: 21694458.
      View in: PubMed
    14. Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell D. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010 Feb; 167(2):181-9. PMID: 20008947.
      View in: PubMed
    15. Reaven GM, Lieberman JA, Sethuraman G, Kraemer H, Davis JM, Blasey C, Tsuang MT, Schatzberg AF. In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. J Psychiatr Res. 2009 Jul; 43(11):997-1002. PMID: 19268968.
      View in: PubMed
    16. Dunayevich E, Sethuraman G, Enerson M, Taylor CC, Lin D. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes. Schizophr Res. 2006 Sep; 86(1-3):300-8. PMID: 16860974.
      View in: PubMed
    17. Sethuraman G, Taylor CC, Enerson M, Dunayevich E. Response to Kujawa et al. letter-to-the-editor. Schizophr Res. 2006 May; 84(1):172-3. PMID: 16563702.
      View in: PubMed
    18. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006 Mar; 59(3):490-8. PMID: 16453317.
      View in: PubMed
    19. Beasley CM, Sutton VK, Taylor CC, Sethuraman G, Dossenbach M, Naber D. Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment? J Clin Psychopharmacol. 2006 Feb; 26(1):40-4. PMID: 16415704.
      View in: PubMed
    20. Barzman DH, McConville BJ, Masterson B, McElroy S, Sethuraman G, Moore K, Kahwaty AM, Nelson D. Impulsive aggression with irritability and responsive to divalproex: a pediatric bipolar spectrum disorder phenotype? J Affect Disord. 2005 Nov; 88(3):279-85. PMID: 16169087.
      View in: PubMed
    21. Joiner TE, Brown JS, Perez M, Sethuraman G, Sallee FR. The illusion of mental health: in the mind of which beholder? J Pers Assess. 2005 Aug; 85(1):92-7. PMID: 16083388.
      View in: PubMed
    22. Sethuraman G, Taylor CC, Enerson M, Dunayevich E. A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia. Schizophr Res. 2005 Nov 15; 79(2-3):337-40. PMID: 16054802.
      View in: PubMed
    23. Sethuraman G, Fassihi H, Ashton GH, Bansal A, Kabra M, Sharma VK, McGrath JA. An Indian child with Kindler syndrome resulting from a new homozygous nonsense mutation (C468X) in the KIND1 gene. Clin Exp Dermatol. 2005 May; 30(3):286-8. PMID: 15807691.
      View in: PubMed
    24. Jazieh AR, Kopp M, Foraida M, Ghouse M, Khalil M, Savidge M, Sethuraman G. The use of dietary supplements by veterans with cancer. J Altern Complement Med. 2004 Jun; 10(3):560-4. PMID: 15253863.
      View in: PubMed
    25. Chae JH, Nahas Z, Wassermann E, Li X, Sethuraman G, Gilbert D, Sallee FR, George MS. A pilot safety study of repetitive transcranial magnetic stimulation (rTMS) in Tourette's syndrome. Cogn Behav Neurol. 2004 Jun; 17(2):109-17. PMID: 15453520.
      View in: PubMed
    26. Geraghty SR, Pinney SM, Sethuraman G, Roy-Chaudhury A, Kalkwarf HJ. Breast milk feeding rates of mothers of multiples compared to mothers of singletons. Ambul Pediatr. 2004 May-Jun; 4(3):226-31. PMID: 15153054.
      View in: PubMed
    27. Gilbert DL, Bansal AS, Sethuraman G, Sallee FR, Zhang J, Lipps T, Wassermann EM. Association of cortical disinhibition with tic, ADHD, and OCD severity in Tourette syndrome. Mov Disord. 2004 Apr; 19(4):416-25. PMID: 15077239.
      View in: PubMed
    28. Gilbert DL, Batterson JR, Sethuraman G, Sallee FR. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry. 2004 Feb; 43(2):206-14. PMID: 14726728.
      View in: PubMed
    29. Buell JF, Trofe J, Sethuraman G, Hanaway MJ, Beebe TM, Gross TG, Alloway R, First MR, Woodle ES. Donors with central nervous system malignancies: are they truly safe? Transplantation. 2003 Jul 27; 76(2):340-3. PMID: 12883189.
      View in: PubMed
    30. Brehm BJ, Rourke KM, Cassell C, Sethuraman G. Psychosocial outcomes of a pilot multidisciplinary program for weight management. Am J Health Behav. 2003 Jul-Aug; 27(4):348-54. PMID: 12882428.
      View in: PubMed
    31. Kowatch RA, Sethuraman G, Hume JH, Kromelis M, Weinberg WA. Combination pharmacotherapy in children and adolescents with bipolar disorder. Biol Psychiatry. 2003 Jun 01; 53(11):978-84. PMID: 12788243.
      View in: PubMed
    32. Malik IA, Aziz Z, Zaidi SH, Sethuraman G. Gemcitabine and Cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. Am J Clin Oncol. 2003 Apr; 26(2):174-7. PMID: 12714891.
      View in: PubMed
    33. Rourke KM, Brehm BJ, Cassell C, Sethuraman G. Effect of weight change on bone mass in female adolescents. J Am Diet Assoc. 2003 Mar; 103(3):369-72. PMID: 12616262.
      View in: PubMed
    34. Gilbert DL, Dure L, Sethuraman G, Raab D, Lane J, Sallee FR. Tic reduction with pergolide in a randomized controlled trial in children. Neurology. 2003 Feb 25; 60(4):606-11. PMID: 12601100.
      View in: PubMed
    35. Gilbert DL, Sethuraman G, Kotagal U, Buncher CR. Meta-analysis of EEG test performance shows wide variation among studies. Neurology. 2003 Feb 25; 60(4):564-70. PMID: 12601093.
      View in: PubMed
    36. Upadhyaya HP, Brady KT, Liao J, Sethuraman G, Middaugh L, Wharton M, Sallee FR. Neuroendocrine and behavioral responses to dopaminergic agonists in adolescents with alcohol abuse. Psychopharmacology (Berl). 2003 Mar; 166(2):95-101. PMID: 12520313.
      View in: PubMed
    37. Rohatgi N, LaRocca RV, Bard V, Sethuraman G, Foon KA. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas. Am J Hematol. 2002 Jul; 70(3):181-5. PMID: 12111762.
      View in: PubMed
    38. McCormack F, Brody A, Meyer C, Leonard J, Chuck G, Dabora S, Sethuraman G, Colby TV, Kwiatkowski DJ, Franz DN. Pulmonary cysts consistent with lymphangioleiomyomatosis are common in women with tuberous sclerosis: genetic and radiographic analysis. Chest. 2002 Mar; 121(3 Suppl):61S. PMID: 11893688.
      View in: PubMed
    39. Franz DN, Brody A, Meyer C, Leonard J, Chuck G, Dabora S, Sethuraman G, Colby TV, Kwiatkowski DJ, McCormack FX. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med. 2001 Aug 15; 164(4):661-8. PMID: 11520734.
      View in: PubMed
    40. Franz DN, Tudor C, Leonard J, Egelhoff JC, Byars A, Valerius K, Sethuraman G. Lamotrigine therapy of epilepsy in tuberous sclerosis. Epilepsia. 2001 Jul; 42(7):935-40. PMID: 11488895.
      View in: PubMed
    41. Upadhyaya HP, Brady KT, Sethuraman G, Sonne SC, Malcolm R. Venlafaxine treatment of patients with comorbid alcohol/cocaine abuse and attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychopharmacol. 2001 Feb; 21(1):116-8. PMID: 11199938.
      View in: PubMed
    42. Sallee FR, Vrindavanam NS, Liu H, Sethuraman G, Sine L. Fenfluramine challenge in anxious children. Hum Psychopharmacol. 2000 Dec; 15(8):619-629. PMID: 12404615.
      View in: PubMed
    43. Sallee FR, Sethuraman G, Sine L, Liu H. Yohimbine challenge in children with anxiety disorders. Am J Psychiatry. 2000 Aug; 157(8):1236-42. PMID: 10910785.
      View in: PubMed
    44. Richtand NM, Logue AD, Welge JA, Perdiue J, Tubbs LJ, Spitzer RH, Sethuraman G, Geracioti TD. The dopamine D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine. Brain Res. 2000 Jun 09; 867(1-2):239-42. PMID: 10837819.
      View in: PubMed
    45. Gilbert DL, Sethuraman G, Sine L, Peters S, Sallee FR. Tourette's syndrome improvement with pergolide in a randomized, double-blind, crossover trial. Neurology. 2000 Mar 28; 54(6):1310-5. PMID: 10746603.
      View in: PubMed
    46. Hogikyan ND, Sethuraman G. Validation of an instrument to measure voice-related quality of life (V-RQOL). J Voice. 1999 Dec; 13(4):557-69. PMID: 10622521.
      View in: PubMed
    47. Sallee FR, Vrindavanam NS, Deas-Nesmith D, Odom AM, Carson SW, Sethuraman G. Parenteral clomipramine challenge in depressed adolescents: mood and neuroendocrine response. Biol Psychiatry. 1998 Oct 01; 44(7):562-7. PMID: 9787880.
      View in: PubMed
    48. Sallee FR, Koran LM, Pallanti S, Carson SW, Sethuraman G. Intravenous clomipramine challenge in obsessive-compulsive disorder: predicting response to oral therapy at eight weeks. Biol Psychiatry. 1998 Aug 01; 44(3):220-7. PMID: 9693393.
      View in: PubMed
    49. Sallee FR, Richman H, Sethuraman G, Dougherty D, Sine L, Altman-Hamamdzic S. Clonidine challenge in childhood anxiety disorder. J Am Acad Child Adolesc Psychiatry. 1998 Jun; 37(6):655-62. PMID: 9628086.
      View in: PubMed
    50. Sallee FR, Nesbitt L, Jackson C, Sine L, Sethuraman G. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry. 1997 Aug; 154(8):1057-62. PMID: 9247389.
      View in: PubMed
    51. Sallee FR, Vrindavanam NS, Deas-Nesmith D, Carson SW, Sethuraman G. Pulse intravenous clomipramine for depressed adolescents: double-blind, controlled trial. Am J Psychiatry. 1997 May; 154(5):668-73. PMID: 9137123.
      View in: PubMed
    52. Lipinski JF, Sallee FR, Jackson C, Sethuraman G. Dopamine agonist treatment of Tourette disorder in children: results of an open-label trial of pergolide. Mov Disord. 1997 May; 12(3):402-7. PMID: 9159736.
      View in: PubMed
    53. Sallee FR, Richman H, Beach K, Sethuraman G, Nesbitt L. Platelet serotonin transporter in children and adolescents with obsessive-compulsive disorder or Tourette's syndrome. J Am Acad Child Adolesc Psychiatry. 1996 Dec; 35(12):1647-56. PMID: 8973072.
      View in: PubMed
    54. Sallee FR, Dougherty D, Sethuraman G, Vrindavanam N. Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette's syndrome. Biol Psychiatry. 1996 Nov 15; 40(10):1044-50. PMID: 8915564.
      View in: PubMed
    55. Sallee FR, Katikaneni LP, McArthur PD, Ibrahim HM, Nesbitt L, Sethuraman G. Head growth in cocaine-exposed infants: relationship to neonate hair level. J Dev Behav Pediatr. 1995 Apr; 16(2):77-81. PMID: 7790518.
      View in: PubMed
    56. Sallee FR, Nesbitt L, Dougherty D, Hilal R, Nandagopal VS, Sethuraman G. Lymphocyte glucocorticoid receptor: predictor of sertraline response in adolescent major depressive disorder (MDD). Psychopharmacol Bull. 1995; 31(2):339-45. PMID: 7491389.
      View in: PubMed
    57. Sallee FR, Sethuraman G, Rock CM. Effects of pimozide on cognition in children with Tourette syndrome: interaction with comorbid attention deficit hyperactivity disorder. Acta Psychiatr Scand. 1994 Jul; 90(1):4-9. PMID: 7976448.
      View in: PubMed
    58. Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol. 1993 Aug 15; 116(2):176-81. PMID: 8352302.
      View in: PubMed